Positive News SentimentPositive NewsNASDAQ:TWST Twist Bioscience (TWST) Stock Forecast, Price & News $20.34 +0.66 (+3.35%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$19.42▼$20.4850-Day Range$18.62▼$26.5752-Week Range$11.46▼$40.50Volume673,997 shsAverage Volume911,644 shsMarket Capitalization$1.17 billionP/E RatioN/ADividend YieldN/APrice Target$28.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Twist Bioscience MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside40.9% Upside$28.67 Price TargetShort InterestBearish24.70% of Shares Sold ShortDividend StrengthN/ASustainability-1.42Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.73) to ($3.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector617th out of 963 stocksBiological Products, Except Diagnostic Industry97th out of 158 stocks 3.3 Analyst's Opinion Consensus RatingTwist Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.67, Twist Bioscience has a forecasted upside of 40.9% from its current price of $20.34.Amount of Analyst CoverageTwist Bioscience has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted24.70% of the outstanding shares of Twist Bioscience have been sold short.Short Interest Ratio / Days to CoverTwist Bioscience has a short interest ratio ("days to cover") of 12.8, which indicates bearish sentiment.Change versus previous monthShort interest in Twist Bioscience has recently increased by 3.65%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldTwist Bioscience does not currently pay a dividend.Dividend GrowthTwist Bioscience does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreTwist Bioscience has received a 65.93% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Deoxyribonucleic acid (DNA)" and "Monoclonal antibodies for research" products. See details.Environmental SustainabilityThe Environmental Impact score for Twist Bioscience is -1.42. Previous Next 3.2 News and Social Media Coverage News SentimentTwist Bioscience has a news sentiment score of 1.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Twist Bioscience this week, compared to 2 articles on an average week.Search Interest13 people have searched for TWST on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Twist Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Twist Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders11.80% of the stock of Twist Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Twist Bioscience are expected to grow in the coming year, from ($3.73) to ($3.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Twist Bioscience is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Twist Bioscience is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTwist Bioscience has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Twist Bioscience (NASDAQ:TWST) StockTwist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. The company was incorporated in 2013 and is headquartered in South San Francisco, California.Read More TWST Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TWST Stock News HeadlinesAugust 31, 2023 | finance.yahoo.comShould You Add Twist Bioscience Corporation (TWST) to Your Portfolio?August 24, 2023 | msn.comTwist Bioscience: Progress Hidden By Execution Issues And Soft DemandSeptember 24, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.August 7, 2023 | finance.yahoo.comTwist Bioscience to Present at the UBS MedTech, Tools and Genomics Summit 2023August 6, 2023 | markets.businessinsider.comBarclays Sticks to Its Buy Rating for Twist Bioscience (TWST)August 6, 2023 | seekingalpha.comTwist Bioscience: Evaluating Its Conglomerate Of Innovation, Growth, And VulnerabilitiesAugust 5, 2023 | marketwatch.comTwist Bioscience Shares Jump 14% on 3Q Loss, Revenue BeatAugust 5, 2023 | markets.businessinsider.comTwist Bioscience Corp Q3 Loss decreases, beats estimatesSeptember 24, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.August 5, 2023 | finance.yahoo.comTwist Bioscience Reports Fiscal Third Quarter 2023 Financial ResultsAugust 5, 2023 | markets.businessinsider.comTwist Bioscience Stock Soars After Q3 Report - Here's WhyAugust 4, 2023 | seekingalpha.comTwist Bioscience Corporation 2023 Q3 - Results - Earnings Call PresentationAugust 3, 2023 | benzinga.comTwist Bioscience's Earnings OutlookJuly 29, 2023 | finanznachrichten.deTwist Bioscience Corporation: Twist Bioscience and Cancer Research Horizons Enter into Collaboration to Advance Cancer ResearchJuly 18, 2023 | finance.yahoo.comTwist Bioscience and Cancer Research Horizons Enter into Collaboration to Advance Cancer ResearchJune 26, 2023 | finance.yahoo.comTwist Bioscience Publishes Preclinical Data in Diabetes Validating GLP-1R Antagonist Antibody as Potential Treatment for Congenital HyperinsulinismJune 16, 2023 | bizjournals.comSynthetic biology pioneer Twist to cut 212 jobsMay 31, 2023 | finanznachrichten.deTwist Bioscience Corporation: Twist Bioscience to Present at ITF World 2023May 24, 2023 | seekingalpha.comTwist Bioscience: Progress On Margins Could Put A Floor Under The StockMay 19, 2023 | seekingalpha.comReconsidering Twist BiosciencesMay 8, 2023 | msn.comBarclays Maintains Twist Bioscience (TWST) Overweight RecommendationMay 8, 2023 | markets.businessinsider.comAnalyst Ratings for Twist BioscienceMay 7, 2023 | finance.yahoo.comTwist Bioscience Corporation (NASDAQ:TWST) Q2 2023 Earnings Call TranscriptMay 5, 2023 | bizjournals.comDespite record quarterly revenue, Twist Bioscience to cut 25% of workforceMay 5, 2023 | msn.comRecap: Twist Bioscience Q2 EarningsMay 4, 2023 | benzinga.comEarnings Preview: Twist BioscienceApril 20, 2023 | finance.yahoo.comTwist Bioscience Enters into Third Collaboration with Astellas to Support Antibody Discovery for ImmunotherapiesSee More Headlines Receive TWST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address TWST Company Calendar Last Earnings8/04/2023Today9/24/2023Fiscal Year End9/30/2023Next Earnings (Estimated)11/17/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TWST CUSIPN/A CIK1581280 Webwww.twistbioscience.com Phone(800) 719-0671FaxN/AEmployees989Year FoundedN/APrice Target and Rating Average Stock Price Forecast$28.67 High Stock Price Forecast$36.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+40.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-217,860,000.00 Net Margins-88.97% Pretax Margin-88.26% Return on Equity-29.09% Return on Assets-23.84% Debt Debt-to-Equity RatioN/A Current Ratio6.12 Quick Ratio5.62 Sales & Book Value Annual Sales$203.57 million Price / Sales5.74 Cash FlowN/A Price / Cash FlowN/A Book Value$14.01 per share Price / Book1.45Miscellaneous Outstanding Shares57,400,000Free Float50,623,000Market Cap$1.17 billion OptionableNot Optionable Beta1.28 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Emily Marine Leproust Ph.D. (Age 49)Co-Founder, Chairman & CEO Comp: $1.4MDr. Patrick John Finn Ph.D. (Age 51)Pres & COO Comp: $801.78kMr. James M. Thorburn (Age 67)CFO & Principal Accounting Officer Comp: $815.16kMr. Dennis Cho (Age 52)Sr. VP, Gen. Counsel, Sec. and Chief Ethics & Compliance Officer Comp: $537.93kDr. William Charles Banyai Ph.D. (Age 68)Sr. VP of Advanced Devel., GM of Data Storage & Director Comp: $745.64kMr. Robert F. Werner (Age 50)Chief Accounting Officer Mr. Siyuan ChenChief Technology OfficerDr. Aaron K. Sato Ph.D.Chief Scientific OfficerMr. Chet GandhiChief Information OfficerMs. Paula Green (Age 55)Sr. VP of HR More ExecutivesKey CompetitorsPrime MedicineNYSE:PRMEApogee TherapeuticsNASDAQ:APGEProKidneyNASDAQ:PROKRelay TherapeuticsNASDAQ:RLAYReplimune GroupNASDAQ:REPLView All CompetitorsInsiders & InstitutionsVirginia Retirement Systems ET ALBought 30,500 shares on 8/22/2023Ownership: 0.053%California State Teachers Retirement SystemBought 667 shares on 8/21/2023Ownership: 0.120%Osaic Holdings Inc.Bought 1,634 shares on 8/21/2023Ownership: 0.020%Nuveen Asset Management LLCBought 20,320 shares on 8/16/2023Ownership: 0.295%Rockefeller Capital Management L.P.Sold 844 shares on 8/15/2023Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions TWST Stock - Frequently Asked Questions Should I buy or sell Twist Bioscience stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TWST shares. View TWST analyst ratings or view top-rated stocks. What is Twist Bioscience's stock price forecast for 2023? 6 Wall Street analysts have issued 12-month price targets for Twist Bioscience's stock. Their TWST share price forecasts range from $20.00 to $36.00. On average, they anticipate the company's share price to reach $28.67 in the next twelve months. This suggests a possible upside of 40.9% from the stock's current price. View analysts price targets for TWST or view top-rated stocks among Wall Street analysts. How have TWST shares performed in 2023? Twist Bioscience's stock was trading at $23.81 at the start of the year. Since then, TWST stock has decreased by 14.6% and is now trading at $20.34. View the best growth stocks for 2023 here. When is Twist Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, November 17th 2023. View our TWST earnings forecast. How were Twist Bioscience's earnings last quarter? Twist Bioscience Co. (NASDAQ:TWST) released its quarterly earnings results on Friday, August, 4th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.13. The company earned $63.80 million during the quarter, compared to analyst estimates of $60.62 million. Twist Bioscience had a negative trailing twelve-month return on equity of 29.09% and a negative net margin of 88.97%. The firm's quarterly revenue was up 13.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.08) EPS. What ETFs hold Twist Bioscience's stock? ETFs with the largest weight of Twist Bioscience (NASDAQ:TWST) stock in their portfolio include Subversive Mental Health ETF (SANE), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Genomic Revolution ETF (ARKG), Global X Telemedicine & Digital Health ETF (EDOC), ROBO Global Healthcare Technology and Innovation ETF (HTEC), WisdomTree BioRevolution Fund (WDNA), BNY Mellon Innovators ETF (BKIV) and SPDR S&P Biotech ETF (XBI). What guidance has Twist Bioscience issued on next quarter's earnings? Twist Bioscience updated its fourth quarter 2023 earnings guidance on Monday, August, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $63.00 million-$64.00 million, compared to the consensus revenue estimate of $62.25 million. What is Emily Leproust's approval rating as Twist Bioscience's CEO? 44 employees have rated Twist Bioscience Chief Executive Officer Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among the company's employees. What other stocks do shareholders of Twist Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO). When did Twist Bioscience IPO? (TWST) raised $75 million in an initial public offering on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers. What is Twist Bioscience's stock symbol? Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST." Who are Twist Bioscience's major shareholders? Twist Bioscience's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (12.18%), BlackRock Inc. (12.03%), JPMorgan Chase & Co. (8.95%), State Street Corp (8.45%), William Blair Investment Management LLC (6.30%) and Sumitomo Mitsui Trust Holdings Inc. (6.24%). Insiders that own company stock include Dennis Cho, Emily M Leproust, Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess and William Banyai. View institutional ownership trends. How do I buy shares of Twist Bioscience? Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Twist Bioscience's stock price today? One share of TWST stock can currently be purchased for approximately $20.34. How much money does Twist Bioscience make? Twist Bioscience (NASDAQ:TWST) has a market capitalization of $1.17 billion and generates $203.57 million in revenue each year. The company earns $-217,860,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis. How many employees does Twist Bioscience have? The company employs 989 workers across the globe. How can I contact Twist Bioscience? Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.twistbioscience.com. The company can be reached via phone at (800) 719-0671 or via email at maeve@argotpartners.com. This page (NASDAQ:TWST) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Twist Bioscience Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.